



# Financial Tear Sheet

## Corporate Profile

Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem's product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and a Phase 2 study in refractory indolent Non-Hodgkin's Lymphoma (iNHL). Verastem plans to share these clinical data with the U.S. Food and Drug Administration (FDA) with the goal of filing a New Drug Application (NDA) with the FDA during the first half of 2018. Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.

## Primary IR Contact

Marianne M. Lambertson  
Vice President, Corporate  
Communications

**Phone:** 781-292-4273

**E-mail:**

[mlambertson@verastem.com](mailto:mlambertson@verastem.com)

## Stock Performance

### VSTM (Common Stock)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	\$5.24
<b>Change (%)</b>	▲ 0.22 (4.38%)
<b>Volume</b>	1,618,967
<b>52 Week Low</b>	\$1.92
<b>Market Cap</b>	\$307,827,735
<b>Rolling EPS</b>	-1.82
<b>PE Ratio</b>	N/A
<b>Shares Outstanding</b>	58,745,751

Data as of May 21, 2018 2:33 p.m. ET



## Recent Headlines & Events

May 16, 2018 - 5:09 p.m.

[Verastem Oncology to Present Data on Two Lead Drug Candidates at ASCO 2018 Annual Meeting](#)

May 16, 2018 - 9:30 a.m.

[Verastem Oncology Announces Pricing of Public Offering of Common Stock](#)

May 15, 2018 - 4:01 p.m.

[Verastem Oncology Announces Public Offering of Common Stock](#)

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
05/18/18	<a href="#">424B5</a>
05/18/18	<a href="#">8-K</a>
05/15/18	<a href="#">424B5</a>
05/03/18	<a href="#">10-Q</a>

## Corporate Governance

<a href="#">Robert Forrester, LL.B.</a>	President/Chief Executive Officer
<a href="#">Dan Paterson</a>	Chief Operating Officer
<a href="#">Steven Bloom</a>	Chief Strategy Officer
<a href="#">Julie Feder</a>	Chief Financial Officer
<a href="#">Diep Le, M.D., Ph.D.</a>	Chief Medical Officer
<a href="#">Joseph Lobacki</a>	Chief Commercial Officer
<a href="#">Jonathan Pachter, Ph.D.</a>	Chief Scientific Officer
<a href="#">Hagop Youssoufian, MSc, M.D.</a>	Head of Hematology and Oncology Development

Data provided by Nasdaq. Minimum 15 minutes delayed.